.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Argus Health
Chinese Patent Office
Boehringer Ingelheim
Mallinckrodt
Fuji
US Army
Covington
Deloitte
Federal Trade Commission

Generated: December 14, 2017

DrugPatentWatch Database Preview

Chiesi Usa Inc Company Profile

« Back to Dashboard

What is the competitive landscape for CHIESI USA INC, and when can generic versions of CHIESI USA INC drugs launch?

CHIESI USA INC has nine approved drugs.

There are seventeen US patents protecting CHIESI USA INC drugs on CHIESI USA INC drugs in the past three years.

There are two hundred and thirty patent family members on CHIESI USA INC drugs in forty-six countries and fourteen supplementary protection certificates in nine countries.

Summary for Chiesi Usa Inc

International Patents:230
US Patents:17
Tradenames:12
Ingredients:6
NDAs:9
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Chiesi Usa IncCARDENEnicardipine hydrochlorideINJECTABLE;INJECTION019734-001Jan 30, 1992APRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Chiesi Usa IncCARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINERnicardipine hydrochlorideINJECTABLE;INTRAVENOUS019734-003Jul 31, 2008RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Chiesi Usa IncCARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINERnicardipine hydrochlorideINJECTABLE;INTRAVENOUS019734-003Jul 31, 2008RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Chiesi Usa IncKENGREALcangrelorPOWDER;IV (INFUSION)204958-001Jun 22, 2015RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Chiesi Usa IncCARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINERnicardipine hydrochlorideINJECTABLE;INTRAVENOUS019734-004Nov 7, 2008RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Chiesi Usa IncKENGREALcangrelorPOWDER;IV (INFUSION)204958-001Jun 22, 2015RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Chiesi Usa IncCARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINERnicardipine hydrochlorideINJECTABLE;INTRAVENOUS019734-003Jul 31, 2008RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Chiesi Usa IncKENGREALcangrelorPOWDER;IV (INFUSION)204958-001Jun 22, 2015RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Chiesi Usa IncCARDENE SRnicardipine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL020005-003Feb 21, 1992DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Chiesi Usa IncCARDENEnicardipine hydrochlorideCAPSULE;ORAL019488-001Dec 21, 1988DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Chiesi Usa Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Chiesi Usa IncKENGREALcangrelorPOWDER;IV (INFUSION)204958-001Jun 22, 2015► Subscribe► Subscribe
Chiesi Usa IncCARDENEnicardipine hydrochlorideCAPSULE;ORAL019488-001Dec 21, 1988► Subscribe► Subscribe
Chiesi Usa IncCARDENEnicardipine hydrochlorideINJECTABLE;INJECTION019734-001Jan 30, 1992► Subscribe► Subscribe
Chiesi Usa IncCLEVIPREXclevidipineEMULSION;INTRAVENOUS022156-003Nov 8, 2013► Subscribe► Subscribe
Chiesi Usa IncCARDENE SRnicardipine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL020005-001Feb 21, 1992► Subscribe► Subscribe
Chiesi Usa IncCLEVIPREXclevidipineEMULSION;INTRAVENOUS022156-001Aug 1, 2008► Subscribe► Subscribe
Chiesi Usa IncZYFLO CRzileutonTABLET, EXTENDED RELEASE;ORAL022052-001May 30, 2007► Subscribe► Subscribe
Chiesi Usa IncZYFLOzileutonTABLET;ORAL020471-003Dec 9, 1996► Subscribe► Subscribe
Chiesi Usa IncCARDENE SRnicardipine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL020005-003Feb 21, 1992► Subscribe► Subscribe
Chiesi Usa IncCARDENE SRnicardipine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL020005-002Feb 21, 1992► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for CHIESI USA INC drugs

Drugname Dosage Strength Tradename Submissiondate
tobramycinInhalation Solution300 mg/4 mLBETHKIS8/31/2017
nicardipine hydrochlorideInjection0.1 mg/mL, 200 mL and0.2mg/mL, 200 mLCARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER6/20/2013
nicardipine hydrochlorideInjection2.5 mg/mL, 10 mL AmpoulesCARDENE12/27/2006

Non-Orange Book Patents for Chiesi Usa Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,320,754Maintenance of platelet inhibition during antiplatelet therapy► Subscribe
8,168,598Optimised formulation of tobramycin for aerosolization► Subscribe
8,716,261Maintenance of platelet inhibition during antiplatelet therapy► Subscribe
9,549,994Compositions of nicardipine and sulfoalkylated .beta.-cyclodextrin► Subscribe
9,370,586Methods of preparing pre-mixed, ready-to-use pharmaceutical compositions► Subscribe
7,659,290Methods of preparing pre-mixed, ready-to-use pharmaceutical compositions► Subscribe
8,871,736Maintenance of platelet inhibition during antiplatelet therapy► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Chiesi Usa Inc Drugs

Country Document Number Estimated Expiration
South Korea20160032266► Subscribe
Australia2016204562► Subscribe
Slovenia1000079► Subscribe
Poland2276541► Subscribe
Japan4262086► Subscribe
Sweden9604795► Subscribe
New Zealand572226► Subscribe
Slovenia1007094► Subscribe
Hong Kong1026366► Subscribe
World Intellectual Property Organization (WIPO)2012051116► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Chiesi Usa Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0722Netherlands► SubscribePRODUCT NAME: TOBRAMYCINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: C(2011)5394 20110720
/2015Austria► SubscribePRODUCT NAME: TOBRAMYCIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/10/652/001-003 20110720
2015 00017Denmark► SubscribePRODUCT NAME: TOBRAMYCIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/10/652/001-003 20110720
00520Netherlands► SubscribePRODUCT NAME: CLEVIDIPINE; NAT. REGISTRATION NO/DATE: RVG 104771 20111129; FIRST REGISTRATION: PL 16881/0003 20111123
209Luxembourg► SubscribePRODUCT NAME: CLEVIDIPINE SOUS TOUTES LES FORMES PROCURANT UNE PROTECTION A PARTIR DU BREVET DE BASE
C0053France► SubscribePRODUCT NAME: CLEVIDIPINE; NAT. REGISTRATION NO/DATE: NL 37621 20120725; FIRST REGISTRATION: GB - PL 16881/0003 20111123
90008-0Sweden► SubscribePRODUCT NAME: CLEVIDIPINE; NAT. REG. NO/DATE: 42321 20120120; FIRST REG.: GB PL 16881/0003 20111123
0726894/01Switzerland► SubscribePRODUCT NAME: RACEMISCHES CLEVIDIPINBUTYRAT; REGISTRATION NO/DATE: SWISSMEDIC 60117 11.06.2010
2015000021Germany► SubscribePRODUCT NAME: TOBRAMYCIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/10/652/001-003 20110720
C/GB12/011United Kingdom► SubscribePRODUCT NAME: CLEVIDIPINE; REGISTERED: UK PL16881/0003 20111123
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
US Army
Baxter
Accenture
Daiichi Sankyo
Julphar
Cipla
Citi
Cantor Fitzgerald
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot